this work references cited by second hopReferences
- 2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement83,813 cited
- 2009Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement19,577 cited
- 2016Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial2,196 cited
- 2016Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial1,696 cited
- 2006Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance1,682 cited
- 2016Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study1,533 cited
- 2021Trial of Psilocybin versus Escitalopram for Depression1,386 cited
- 2020Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder1,296 cited
- 2010Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer1,205 cited
- 2008Human hallucinogen research: guidelines for safety1,201 cited
- 2015Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study1,150 cited
- 2021MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study996 cited
- 2017Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work